GenMark Diagnostics Profit Margin 2010-2018 | GNMK
Current and historical gross margin, operating margin and net profit margin for GenMark Diagnostics (GNMK) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. GenMark Diagnostics net profit margin as of December 31, 2018 is -71.37%.
|GenMark Diagnostics Annual Profit Margins
|GenMark Diagnostics Quarterly Profit Margins
||Medical Instruments Manufacturing
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor? XT-8 system is the second generation in GenMark Dx's eSensor? platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.